Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

News

‘Elon Musk Pushes Forward With Twitter Payment Master Plan’ – Financial Times

https://www.ft.com/content/9d84d534-b2dd-4cff-85d1-aee137b26a45

byHappy Mohamed

January 30, 2023

1 minute read

https://www.ft.com/content/9d84d534-b2dd-4cff-85d1-aee137b26a45

The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO

By Shanthi Rexaline

Today, 4:55 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

AMAM

Bill Ackman Turns Heat On PepsiCo, Coca-Cola But Warren Buffett Fan Points Finger Back: What About Pershing’s Own Top 4 Holdings?

By Shanthi Rexaline

Today, 4:55 AM

Pershing Square’s Bill Ackman took to Twitter on Monday to slam PepsiCo (NYSE: PEP) a

BRKA

News
Tech

Tesla Hikes Prices Yet Again In The US For Some Model 3 Variants

By Rachit Vats

Today, 4:55 AM

Tesla Inc (NASDAQ: TSLA) on Wednesday raised the prices of some of its electric vehicles for the third time in less than a month in the United States, as the company grapples with inflationary pressure and logistical snarls.

TSLA

Oncternal Therapeutics Announces Clinical Trial Collaboration To Advance Zilovertamab Phase 3 Study In Combination With Ibrutinib For Patients With MCL

By Benzinga Newsdesk

Today, 4:55 AM

Clinical trial collaboration supports global registrational Phase 3 study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinib Agreement is supportive of the planned initiation

ONCT

‘Elon Musk Pushes Forward With Twitter Payment Master Plan’ – Financial Times

Related Posts

The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO

Bill Ackman Turns Heat On PepsiCo, Coca-Cola But Warren Buffett Fan Points Finger Back: What About Pershing’s Own Top 4 Holdings?

Tesla Hikes Prices Yet Again In The US For Some Model 3 Variants

Oncternal Therapeutics Announces Clinical Trial Collaboration To Advance Zilovertamab Phase 3 Study In Combination With Ibrutinib For Patients With MCL